MX387891B - Preparación inyectable que comprende una composición en gel de aripiprazol y polinilpirrolidona como agente de suspensión y el uso de la misma para tratar esquizofrenia, trastorno bipolar o depresión - Google Patents
Preparación inyectable que comprende una composición en gel de aripiprazol y polinilpirrolidona como agente de suspensión y el uso de la misma para tratar esquizofrenia, trastorno bipolar o depresiónInfo
- Publication number
- MX387891B MX387891B MX2018010879A MX2018010879A MX387891B MX 387891 B MX387891 B MX 387891B MX 2018010879 A MX2018010879 A MX 2018010879A MX 2018010879 A MX2018010879 A MX 2018010879A MX 387891 B MX387891 B MX 387891B
- Authority
- MX
- Mexico
- Prior art keywords
- injectable preparation
- suspending agent
- sup
- polynylpyrrolidone
- aripiprazole
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 4
- 239000000375 suspending agent Substances 0.000 title abstract 2
- 208000020925 Bipolar disease Diseases 0.000 title 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title 1
- 229960004372 aripiprazole Drugs 0.000 title 1
- 208000028683 bipolar I disease Diseases 0.000 title 1
- 208000025307 bipolar depression Diseases 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 239000002612 dispersion medium Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940071643 prefilled syringe Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636938P | 2012-04-23 | 2012-04-23 | |
| US201361792089P | 2013-03-15 | 2013-03-15 | |
| PCT/JP2013/062683 WO2013162048A1 (en) | 2012-04-23 | 2013-04-23 | Injectable preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX387891B true MX387891B (es) | 2025-03-19 |
Family
ID=48614096
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010879A MX387891B (es) | 2012-04-23 | 2013-04-23 | Preparación inyectable que comprende una composición en gel de aripiprazol y polinilpirrolidona como agente de suspensión y el uso de la misma para tratar esquizofrenia, trastorno bipolar o depresión |
| MX2014012811A MX359241B (es) | 2012-04-23 | 2013-04-23 | Preparación inyectable que comprende una composición en gel que comprende aripiprazol o brexpiprazol como agentes de suspensión. |
| MX2026000814A MX2026000814A (es) | 2012-04-23 | 2021-12-16 | Preparacion inyectable |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014012811A MX359241B (es) | 2012-04-23 | 2013-04-23 | Preparación inyectable que comprende una composición en gel que comprende aripiprazol o brexpiprazol como agentes de suspensión. |
| MX2026000814A MX2026000814A (es) | 2012-04-23 | 2021-12-16 | Preparacion inyectable |
Country Status (31)
| Country | Link |
|---|---|
| US (9) | US20150093442A1 (enExample) |
| EP (2) | EP3539534A1 (enExample) |
| JP (7) | JP6234996B2 (enExample) |
| KR (5) | KR20240068788A (enExample) |
| CN (3) | CN104470499B (enExample) |
| AR (1) | AR090776A1 (enExample) |
| AU (6) | AU2013253374B2 (enExample) |
| BR (1) | BR112014026307B1 (enExample) |
| CA (2) | CA3120297A1 (enExample) |
| CO (1) | CO7151500A2 (enExample) |
| CY (1) | CY1122252T1 (enExample) |
| DK (1) | DK2841054T4 (enExample) |
| EA (1) | EA026619B1 (enExample) |
| ES (1) | ES2743706T5 (enExample) |
| HR (1) | HRP20191366T4 (enExample) |
| HU (1) | HUE045979T2 (enExample) |
| IL (1) | IL235299B (enExample) |
| JO (2) | JOP20200109A1 (enExample) |
| LT (1) | LT2841054T (enExample) |
| MX (3) | MX387891B (enExample) |
| MY (3) | MY210484A (enExample) |
| NZ (1) | NZ630335A (enExample) |
| PH (2) | PH12014502379B1 (enExample) |
| PL (1) | PL2841054T5 (enExample) |
| PT (1) | PT2841054T (enExample) |
| SG (3) | SG11201406451SA (enExample) |
| SI (1) | SI2841054T2 (enExample) |
| TW (6) | TW202425992A (enExample) |
| UA (1) | UA115444C2 (enExample) |
| WO (1) | WO2013162048A1 (enExample) |
| ZA (1) | ZA201407335B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| CN105461703B (zh) * | 2014-12-29 | 2019-05-17 | 深圳市泛谷药业股份有限公司 | 一种brexpiprazole的制备方法 |
| JP6513461B2 (ja) * | 2015-04-14 | 2019-05-15 | 帝國製薬株式会社 | ブレクスピプラゾールの経皮吸収製剤 |
| CN104829603A (zh) * | 2015-05-19 | 2015-08-12 | 杭州新博思生物医药有限公司 | A晶型依匹唑派盐酸盐及其制备方法 |
| US10501450B2 (en) | 2016-02-01 | 2019-12-10 | Hexal Ag | Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations |
| WO2018137708A1 (zh) * | 2017-01-26 | 2018-08-02 | 重庆莱美药业股份有限公司 | 一种纳米炭-铁复合体系及其组合物、制备方法和用途 |
| WO2019213286A1 (en) * | 2018-05-02 | 2019-11-07 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
| US12409153B2 (en) | 2018-11-02 | 2025-09-09 | Amaterasu Lifesciences Llp | Liquid injectable composition |
| WO2021199076A1 (en) * | 2020-03-30 | 2021-10-07 | Cipla Limited | Injectable aripiprazole formulation |
| US20230129919A1 (en) * | 2020-04-01 | 2023-04-27 | Otsuka Pharmaceutical Co., Ltd. | Methods for dose initiation of aripiprazole treatments |
| US20230372317A1 (en) * | 2020-10-27 | 2023-11-23 | Pts Consulting, Llc | A liquid injectable composition of donepezil |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| US11910794B2 (en) | 2021-03-08 | 2024-02-27 | Monsanto Technology Llc | Solutions and methods for long-term pollen storage |
| WO2023067664A1 (ja) * | 2021-10-18 | 2023-04-27 | 大塚製薬株式会社 | ベンゾチオフェン化合物の新規結晶形及びその製造方法 |
| JP7760615B2 (ja) * | 2022-06-16 | 2025-10-27 | ウィズダム・ファーマスーティカル・カンパニー・リミテッド | 薬物組成物及びブレクスピプラゾール口腔内溶解フィルム |
| JP2024016759A (ja) * | 2022-07-26 | 2024-02-07 | ニプロ株式会社 | アリピプラゾール懸濁液の製造方法 |
| CN115969785A (zh) * | 2022-12-30 | 2023-04-18 | 辰欣药业股份有限公司 | 一种阿立哌唑注射剂及其制备方法 |
| WO2024194955A1 (en) * | 2023-03-17 | 2024-09-26 | Otsuka Pharmaceutical Co., Ltd. | Methods of dispersing aripiprazole injectable preparations |
| CN120957722A (zh) | 2023-04-26 | 2025-11-14 | 大塚制药株式会社 | 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动 |
| CN121866045A (zh) * | 2023-09-08 | 2026-04-14 | 广州玻思韬控释药业有限公司 | 注射用凝胶 |
| WO2025183016A1 (ja) * | 2024-02-26 | 2025-09-04 | 大塚製薬株式会社 | Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864100A (en) * | 1957-04-09 | 1961-03-29 | Pfizer & Co C | Therapeutic pencillin compositions and the preparation thereof |
| JPS5913714A (ja) | 1982-07-13 | 1984-01-24 | Taito Pfizer Kk | 外用消炎鎮痛剤 |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| JP4012994B2 (ja) | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| PE20030445A1 (es) * | 2001-09-25 | 2003-07-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| JP2003171264A (ja) * | 2001-12-07 | 2003-06-17 | Taiyo Yakuhin Kogyo Kk | マイクロカプセル及びその製造方法 |
| JP2003238393A (ja) | 2002-02-15 | 2003-08-27 | Otsuka Pharmaceut Co Ltd | 施錠性が改善された錠剤及びその製造方法 |
| NZ537995A (en) | 2002-08-20 | 2007-11-30 | Bristol Myers Squibb Co | Inclusion complex of aripiprazole in a substituted b-cyclodextrin |
| WO2004060374A1 (en) | 2002-12-27 | 2004-07-22 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| TWI258470B (en) | 2003-01-09 | 2006-07-21 | Otsuka Pharma Co Ltd | Process for preparing aripiprazole |
| US7658998B2 (en) | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| CA2523484A1 (en) * | 2003-05-02 | 2004-11-11 | Rimon Therapeutics Ltd. | Thermally reversible implant |
| ZA200508306B (en) | 2003-05-23 | 2007-03-28 | Otsuka Pharma Co Ltd | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| US6987111B2 (en) | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| BRPI0415531B8 (pt) * | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| TWI371274B (en) | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| CN1893931B (zh) | 2003-10-27 | 2011-07-20 | 陶氏康宁公司 | 局部用制剂及将活性剂传递给基底的方法 |
| KR101242486B1 (ko) | 2004-01-12 | 2013-03-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 장기 전달을 위한 제형 및 그의 이용 방법 |
| JP2006219380A (ja) * | 2005-02-08 | 2006-08-24 | Minofuaagen Seiyaku:Kk | グリチルリチン皮下注射製剤 |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| WO2007035348A2 (en) | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| EP1948271B1 (en) | 2005-11-17 | 2013-10-02 | Zogenix, Inc. | Delivery of viscous formulations by needle-free injection |
| JP4373983B2 (ja) | 2006-01-27 | 2009-11-25 | 三菱電機インフォメーションシステムズ株式会社 | 流通経路管理装置及び流通経路管理プログラム |
| GB0618879D0 (en) * | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| US20100098735A1 (en) * | 2006-10-05 | 2010-04-22 | Rajesh Jain | Injectable depot compositions and its process of preparation |
| JP4540700B2 (ja) | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| US20100151459A1 (en) | 2007-01-26 | 2010-06-17 | Jun Soo Kwon | Marker for detecting the proposed efficacy of treatment |
| KR101892745B1 (ko) | 2007-06-25 | 2018-08-28 | 오쓰까 세이야꾸 가부시키가이샤 | 코어/셀 구조를 가진 미소구 |
| LT2170279T (lt) * | 2007-07-31 | 2018-03-12 | Otsuka Pharmaceutical Co., Ltd. | Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai |
| WO2009026473A2 (en) * | 2007-08-21 | 2009-02-26 | Hollis-Eden Pharmaceuticals, Inc. | Stabilized therapeutic compositions and formulations |
| JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| JP2009286740A (ja) | 2008-05-30 | 2009-12-10 | Otsuka Pharmaceut Co Ltd | アリピプラゾールを含有する逆耐性抑制剤 |
| TR200809200A1 (tr) * | 2008-12-01 | 2009-12-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Meloksikam içeren farmasötik formülasyonlar |
| JP6072539B2 (ja) | 2009-05-27 | 2017-02-01 | アルカーメス ファーマ アイルランド リミテッド | ナノ粒子活性物質組成物におけるフレーク状凝集の軽減 |
| KR20120065392A (ko) | 2009-09-11 | 2012-06-20 | 오츠카 세이야쿠 가부시키가이샤 | 만성 동통 치료제 |
| JP5575269B2 (ja) * | 2010-08-24 | 2014-08-20 | 大塚製薬株式会社 | カルボスチリル誘導体並びにシリコーンオイル及び／又はシリコーンオイル誘導体を含有する懸濁液及びケーキ組成物 |
| US9469630B2 (en) * | 2010-10-18 | 2016-10-18 | Sumitomo Dainippon Pharma Co., Ltd. | Sustained-release formulation for injection |
| AR083884A1 (es) | 2010-11-16 | 2013-03-27 | Otsuka Pharma Co Ltd | Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa |
| JP2012121850A (ja) | 2010-12-09 | 2012-06-28 | Otsuka Pharmaceut Co Ltd | アリピプラゾールの経口速溶性組成物 |
| CN105125509B (zh) | 2011-01-24 | 2019-01-11 | 大塚制药株式会社 | 以阿立哌唑作为有效成分的块状组合物 |
| TWI636784B (zh) | 2011-04-05 | 2018-10-01 | 大塚製藥股份有限公司 | 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途 |
| JP2012232958A (ja) † | 2011-05-09 | 2012-11-29 | Otsuka Pharmaceut Co Ltd | 注射製剤 |
| JO3410B1 (ar) | 2011-06-07 | 2019-10-20 | Otsuka Pharma Co Ltd | تركيبة أريبيبرازول مجفف بالتبريد |
| US9241876B2 (en) | 2011-06-27 | 2016-01-26 | Shanghai Zhongxi Pharmaceutical Corporation | Aripiprazole medicament formulation and preparation method therefor |
| TW201309651A (zh) | 2011-06-29 | 2013-03-01 | Otsuka Pharma Co Ltd | 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法 |
| ES2601457T3 (es) | 2011-07-28 | 2017-02-15 | Otsuka Pharmaceutical Co., Ltd. | Método para producir compuestos de benzo[b]tiofeno |
| JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| JO3753B1 (ar) | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| AR088372A1 (es) | 2011-10-19 | 2014-05-28 | Otsuka Pharma Co Ltd | Solucion para administracion oral |
| JP2013139441A (ja) | 2011-12-28 | 2013-07-18 | Otsuka Pharmaceut Co Ltd | マイクロスフェア |
| TW201332572A (zh) | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| TW201343201A (zh) | 2012-03-06 | 2013-11-01 | Otsuka Pharma Co Ltd | 持續釋放型口服固體製劑 |
| TWI562991B (en) | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| AR090775A1 (es) | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
-
2012
- 2012-04-23 JO JOP/2020/0109A patent/JOP20200109A1/ar unknown
-
2013
- 2013-04-22 AR ARP130101321A patent/AR090776A1/es not_active Application Discontinuation
- 2013-04-23 US US14/396,380 patent/US20150093442A1/en not_active Abandoned
- 2013-04-23 NZ NZ630335A patent/NZ630335A/en unknown
- 2013-04-23 AU AU2013253374A patent/AU2013253374B2/en active Active
- 2013-04-23 JO JOP/2013/0116A patent/JO3632B1/ar active
- 2013-04-23 SG SG11201406451SA patent/SG11201406451SA/en unknown
- 2013-04-23 TW TW112130297A patent/TW202425992A/zh unknown
- 2013-04-23 WO PCT/JP2013/062683 patent/WO2013162048A1/en not_active Ceased
- 2013-04-23 KR KR1020247015029A patent/KR20240068788A/ko not_active Ceased
- 2013-04-23 KR KR1020257041228A patent/KR20260003375A/ko active Pending
- 2013-04-23 KR KR1020207015451A patent/KR102498075B1/ko active Active
- 2013-04-23 SG SG10201608753UA patent/SG10201608753UA/en unknown
- 2013-04-23 CA CA3120297A patent/CA3120297A1/en active Pending
- 2013-04-23 CN CN201380021440.9A patent/CN104470499B/zh active Active
- 2013-04-23 KR KR1020147032714A patent/KR102138852B1/ko active Active
- 2013-04-23 LT LTEP13728542.5T patent/LT2841054T/lt unknown
- 2013-04-23 CA CA2869889A patent/CA2869889C/en active Active
- 2013-04-23 TW TW111116460A patent/TW202313036A/zh unknown
- 2013-04-23 HU HUE13728542A patent/HUE045979T2/hu unknown
- 2013-04-23 BR BR112014026307-8A patent/BR112014026307B1/pt active IP Right Grant
- 2013-04-23 JP JP2015506529A patent/JP6234996B2/ja active Active
- 2013-04-23 SG SG10201913425VA patent/SG10201913425VA/en unknown
- 2013-04-23 EP EP19169193.0A patent/EP3539534A1/en active Pending
- 2013-04-23 EP EP13728542.5A patent/EP2841054B2/en active Active
- 2013-04-23 MX MX2018010879A patent/MX387891B/es unknown
- 2013-04-23 TW TW113144877A patent/TW202535396A/zh unknown
- 2013-04-23 PT PT13728542T patent/PT2841054T/pt unknown
- 2013-04-23 PL PL13728542.5T patent/PL2841054T5/pl unknown
- 2013-04-23 DK DK13728542.5T patent/DK2841054T4/da active
- 2013-04-23 MY MYPI2023004225A patent/MY210484A/en unknown
- 2013-04-23 MY MYPI2018001894A patent/MY198007A/en unknown
- 2013-04-23 SI SI201331550T patent/SI2841054T2/sl unknown
- 2013-04-23 EA EA201491685A patent/EA026619B1/ru not_active IP Right Cessation
- 2013-04-23 TW TW102114410A patent/TWI637752B/zh active
- 2013-04-23 TW TW109130917A patent/TW202126303A/zh unknown
- 2013-04-23 CN CN202210169142.5A patent/CN114344259B/zh active Active
- 2013-04-23 ES ES13728542T patent/ES2743706T5/es active Active
- 2013-04-23 TW TW107109282A patent/TWI713826B/zh active
- 2013-04-23 MY MYPI2014002932A patent/MY178573A/en unknown
- 2013-04-23 KR KR1020217029406A patent/KR20210116702A/ko not_active Ceased
- 2013-04-23 MX MX2014012811A patent/MX359241B/es active IP Right Grant
- 2013-04-23 HR HRP20191366TT patent/HRP20191366T4/hr unknown
- 2013-04-23 UA UAA201411954A patent/UA115444C2/uk unknown
- 2013-04-23 CN CN201810143716.5A patent/CN108186556B/zh active Active
-
2014
- 2014-10-09 ZA ZA2014/07335A patent/ZA201407335B/en unknown
- 2014-10-23 PH PH12014502379A patent/PH12014502379B1/en unknown
- 2014-10-23 IL IL235299A patent/IL235299B/en active IP Right Grant
- 2014-11-21 CO CO14256422A patent/CO7151500A2/es unknown
-
2017
- 2017-09-11 US US15/701,202 patent/US20180055941A1/en not_active Abandoned
- 2017-09-14 AU AU2017228608A patent/AU2017228608C1/en active Active
- 2017-10-25 JP JP2017206658A patent/JP6470378B2/ja active Active
-
2018
- 2018-10-10 US US16/156,958 patent/US10517951B2/en active Active
-
2019
- 2019-01-07 AU AU2019200060A patent/AU2019200060A1/en not_active Abandoned
- 2019-01-16 JP JP2019005031A patent/JP2019070028A/ja active Pending
- 2019-03-07 PH PH12019500498A patent/PH12019500498A1/en unknown
- 2019-07-17 US US16/514,973 patent/US20190336607A1/en not_active Abandoned
- 2019-08-28 CY CY20191100912T patent/CY1122252T1/el unknown
-
2020
- 2020-02-07 US US16/785,268 patent/US20200179517A1/en not_active Abandoned
- 2020-06-24 AU AU2020204200A patent/AU2020204200B2/en active Active
- 2020-10-14 JP JP2020172902A patent/JP2021008512A/ja active Pending
- 2020-12-01 US US17/108,939 patent/US11097007B2/en active Active
-
2021
- 2021-08-04 US US17/444,469 patent/US11638757B2/en active Active
- 2021-12-16 MX MX2026000814A patent/MX2026000814A/es unknown
-
2022
- 2022-01-14 JP JP2022004098A patent/JP7293412B2/ja active Active
- 2022-09-27 AU AU2022241491A patent/AU2022241491B2/en active Active
- 2022-12-30 US US18/148,860 patent/US12016927B2/en active Active
-
2023
- 2023-06-06 JP JP2023092924A patent/JP7612758B2/ja active Active
-
2024
- 2024-05-13 US US18/662,049 patent/US20250121065A1/en active Pending
- 2024-12-24 JP JP2024226861A patent/JP2025041805A/ja active Pending
-
2025
- 2025-01-13 AU AU2025200229A patent/AU2025200229A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2026000814A (es) | Preparacion inyectable | |
| BR112015021709B8 (pt) | Poli(beta-amino ésteres) modificados para administração de fármacos e nanopartícula compreendendo os mesmos, uma composição compreendendo os mesmos, método de encapsulamento de um agente em uma matriz de polímeros para formar nanopartículas, e uso dos poli(beta-amino ésteres) | |
| BR112015017246A8 (pt) | composição farmacêutica aquosa, seu uso e seringa | |
| CL2018000299A1 (es) | Composiciones con potenciadores de impregnacion para el suministro de fármacos. | |
| BR112016002646A2 (pt) | dispositivos e métodos de entrega de fármaco de múltiplas unidades | |
| MX2020006664A (es) | Composiciones liquidas de suministro. | |
| BR112014028600A8 (pt) | Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação | |
| BR112015030260A2 (pt) | soluções concentradas de reticulação com borato para uso em operações de fraturamento hidráulico | |
| NI201400122A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| BR112014014832A8 (pt) | formulação e método de controlar fungos | |
| AR095672A1 (es) | Composiciones farmacéuticas que comprenden everolimus | |
| EP4238580A3 (en) | Transdermal delivery system including an interface mediator | |
| BR112015004613A2 (pt) | agonistas para o receptor trpm-8; combinações de substâncias ativas de agonistas; preparações cosméticas ou dermatológicas contendo um ou mais agonistas de trpm-8, um ou mais polióis, e uma ou mais substâncias de ação antieritematosa ou inibidora de inflamação | |
| PE20160850A1 (es) | Sistema multiparticulado para administrar drogas | |
| UY35848A (es) | Tienopirimidinas | |
| AR105223A1 (es) | Compuestos químicos | |
| BR112021017878A2 (pt) | Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação | |
| BR112018002520A2 (pt) | Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer | |
| CO2019012428A2 (es) | Composición líquida de suspensión de esmectita y método de preparación de la misma | |
| AR102132A1 (es) | Composición cosmética y/o farmacéutica en forma de dispersión, procedimiento de preparación y utilización para el tratamiento de la piel | |
| MX2021015921A (es) | Preparacion inyectable. | |
| ES2422563A1 (es) | Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma | |
| TH157429A (th) | สารเตรียมชนิดฉีดได้ | |
| BR112015022000A8 (pt) | preparação de combinação farmacêutica, composição farmacêutica e uso da preparação de combinação | |
| IN2015CH05309A (enExample) |